In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

Published Date: 20 May 2024

A 42% lower risk of tumor death, progression, or recurrence is demonstrated by the CheckMate 77T trial.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.

2.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

3.

Mortality up for children with leukemia from lowest SES neighborhoods

4.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

5.

Vaccine shows promise for pancreatic cancer, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot